glp-1 anesthesia news Glucagon-Like Peptide-1 Receptor Agonists in Perioperative Care GLP-1 drugs and aspiration risk

It found that people taking Wegovy lost about 12.4% more weight than those who took a placebo (a fake treatment)

In some cases, patients who have not achieved their desired weight loss on Wegovy may benefit from the dual-action mechanism of Zepbound, which has demonstrated greater average weight loss in clinical studies

Breaking any of them compromises the peptide, reduces potency, and can introduce safety concerns

If side effects are still present or appetite has not stabilized at the current dose, stay longer before increasing

Goodman describes his own contributions to the GLP-1 story as trivial. During that early era of molecular biology, people were identifying new genes and peptides all the time

Patents and regulatory exclusivities on glp-1 receptor agonists